Organon & Co. (NYSE:OGN) Receives Average Rating of "Reduce" from Brokerages

Key Points

• Analysts rate Organon “Reduce” overall: Two firms recommend selling and five recommend holding, with an average 12-month price target of $11.40 versus the stock’s recent $13.54 price.
• Organon’s latest quarterly results fell short of expectations, with EPS of $0.71 versus $0.83 expected and revenue of $1.46 billion versus $1.49 billion; revenue declined 3.5% year over year.
• Insider sentiment was positive: Senior Vice President Lynette Holzbaur bought 26,448 shares worth approximately $353,000, while institutional investors own 77.43% of the company.

Shares of Organon & Co. (NYSE:OGN - Get Free Report) have received a consensus rating of "Reduce" from the seven ratings firms that are currently covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell recommendation and five have issued a hold recommendation on the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $11.40.

Several equities research analysts have recently weighed in on the stock. Zacks Research raised shares of Organon & Co. from a "strong sell" rating to a "hold" rating in a research report on Tuesday, April 14th. BNP Paribas Exane reiterated a "neutral" rating and issued a $14.00 price target (up from $12.00) on shares of Organon & Co. in a research note on Wednesday, April 29th. Piper Sandler upgraded Organon & Co. from an "underweight" rating to a "neutral" rating and upped their price objective for the company from $5.00 to $14.00 in a research note on Tuesday, April 28th. Finally, Weiss Ratings raised Organon & Co. from a "hold (c-)" rating to a "hold (c)" rating in a report on Monday, July 13th.

Organon & Co. Stock Up 0.0%

Shares of NYSE:OGN traded up $0.01 during midday trading on Thursday, reaching $13.54. The company had a trading volume of 154,878 shares, compared to its average volume of 6,118,735. The stock has a market capitalization of $3.56 billion, a P/E ratio of 14.56, a PEG ratio of 1.25 and a beta of 1.54. The stock's fifty day moving average price is $13.47 and its 200-day moving average price is $10.34. The company has a debt-to-equity ratio of 9.47, a current ratio of 1.97 and a quick ratio of 1.42. Organon & Co. has a one year low of $5.69 and a one year high of $13.60.

Organon & Co. (NYSE:OGN - Get Free Report) last posted its quarterly earnings data on Thursday, April 30th. The company reported $0.71 EPS for the quarter, missing analysts' consensus estimates of $0.83 by ($0.12). The company had revenue of $1.46 billion for the quarter, compared to the consensus estimate of $1.49 billion. Organon & Co. had a net margin of 3.99% and a return on equity of 99.95%. The company's revenue was down 3.5% compared to the same quarter last year. During the same quarter last year, the company earned $1.02 earnings per share. Equities research analysts expect that Organon & Co. will post 3.23 earnings per share for the current fiscal year.

Insider Activity

In other news, SVP Lynette Holzbaur purchased 26,448 shares of the company's stock in a transaction that occurred on Wednesday, May 6th. The shares were acquired at an average cost of $13.35 per share, with a total value of $353,080.80. Following the transaction, the senior vice president owned 52,851 shares in the company, valued at approximately $705,560.85. The trade was a 100.17% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 1.62% of the company's stock.

Institutional Trading of Organon & Co.

Several institutional investors have recently added to or reduced their stakes in the business. Cetera Investment Advisers lifted its position in shares of Organon & Co. by 1.7% in the 1st quarter. Cetera Investment Advisers now owns 48,073 shares of the company's stock worth $288,000 after buying an additional 788 shares during the last quarter. State of Alaska Department of Revenue raised its stake in Organon & Co. by 0.6% during the fourth quarter. State of Alaska Department of Revenue now owns 278,379 shares of the company's stock worth $1,995,000 after acquiring an additional 1,570 shares during the period. Integrated Wealth Concepts LLC raised its stake in Organon & Co. by 2.8% during the third quarter. Integrated Wealth Concepts LLC now owns 58,648 shares of the company's stock worth $626,000 after acquiring an additional 1,594 shares during the period. Rafferty Asset Management LLC lifted its holdings in Organon & Co. by 8.5% in the second quarter. Rafferty Asset Management LLC now owns 23,578 shares of the company's stock worth $228,000 after acquiring an additional 1,847 shares during the last quarter. Finally, Bank of Nova Scotia lifted its holdings in Organon & Co. by 4.6% in the third quarter. Bank of Nova Scotia now owns 44,512 shares of the company's stock worth $475,000 after acquiring an additional 1,947 shares during the last quarter. Institutional investors own 77.43% of the company's stock.

About Organon & Co.

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.